CATECHOL-O-METHYLTRANSFERASE (COMT) INHIBITOR RO 40-7592 PROLONGS DURATION OF ACTION OF LEVODOPA CARBIDOPA IN PARKINSONIAN-PATIENTS

被引：0
|
作者：
ROBERTS, JW
CORALOCATELLI, G
BRAVI, D
METMAN, LV
MOURADIAN, MM
CHASE, TN
机构：
来源：
NEUROLOGY | 1993年 / 43卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
下载
收藏
页码：A332 / A332
页数：1
相关论文
共 18 条
  • [1] CATECHOL-O-METHYLTRANSFERASE INHIBITOR TOLCAPONE PROLONGS LEVODOPA CARBIDOPA ACTION IN PARKINSONIAN-PATIENTS
    ROBERTS, JW
    CORALOCATELLI, G
    BRAVI, D
    AMANTEA, MA
    MOURADIAN, MM
    CHASE, TN
    NEUROLOGY, 1993, 43 (12) : 2685 - 2688
  • [2] PROLONGATION OF LEVODOPA-INDUCED ON MOTOR PERIODS BY RO 40-7592, A CATECHOL-O-METHYLTRANSFERASE INHIBITOR IN PARKINSONS-DISEASE
    POLLAK, P
    LIMOUSIN, P
    GERVASON, CL
    PERRET, JE
    ANNALS OF NEUROLOGY, 1993, 34 (02) : 316 - 316
  • [3] EFFECT OF PERIPHERAL CATECHOL-O-METHYLTRANSFERASE INHIBITION ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF LEVODOPA IN PARKINSONIAN-PATIENTS
    NUTT, JG
    WOODWARD, WR
    BECKNER, RM
    STONE, CK
    BERGGREN, K
    CARTER, JH
    GANCHER, ST
    HAMMERSTAD, JP
    GORDIN, A
    NEUROLOGY, 1994, 44 (05) : 913 - 919
  • [4] EXTRACELLULAR CONCENTRATIONS OF DOPAMINE AND METABOLITES IN THE RAT CAUDATE AFTER ORAL-ADMINISTRATION OF A NOVEL CATECHOL-O-METHYLTRANSFERASE INHIBITOR RO 40-7592
    ACQUAS, E
    CARBONI, E
    DEREE, RHA
    DAPRADA, M
    DICHIARA, G
    JOURNAL OF NEUROCHEMISTRY, 1992, 59 (01) : 326 - 330
  • [5] Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits
    DaPrada, M
    Jorga, KM
    CLINICAL NEUROPHARMACOLOGY, 1996, 19 (01) : 98 - 99
  • [6] DETERMINATION OF THE CATECHOL-O-METHYLTRANSFERASE INHIBITOR RO-40-7592 IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH COULOMETRIC DETECTION
    TIMM, U
    ERDIN, R
    JOURNAL OF CHROMATOGRAPHY, 1992, 593 (1-2): : 63 - 68
  • [7] Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa
    LeWitt, Peter
    Liang, Grace S.
    Olanow, C. Warren
    Kieburtz, Karl D.
    Jimenez, Roland
    Olson, Kurt
    Klepitskaya, Olga
    Loewen, Gordon
    CLINICAL NEUROPHARMACOLOGY, 2023, 46 (02) : 43 - 50
  • [8] Catechol-O-methyltransferase inhibition with tolcapone reduces the ''wearing off'' phenomenon and levodopa requirements in fluctuating parkinsonian patients
    Baas, H
    Beiske, AG
    Ghika, J
    Jackson, M
    Oertel, WH
    Poewe, W
    Ransmayr, G
    Auff, E
    Volc, D
    Dupont, E
    Mikkelsen, B
    Wermuth, L
    WommPetersen, J
    Benecke, R
    Eichhom, T
    Kolbe, H
    Oertel, W
    Schimrigk, K
    Olsson, JE
    Palhagen, S
    Burgunder, JM
    Ghika, A
    Regli, F
    Steck, A
    Medcalf, P
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 63 (04): : 421 - 428
  • [9] The effect of catechol-O-methyltransferase polymorphism on the levodopa pharmacokinetics after co-administration of single dose of levodopa and entacapone in Parkinsonian patients
    Wu, RM
    Yu, IW
    Ho, YF
    Kuo, JW
    Chern, H
    MOVEMENT DISORDERS, 2002, 17 : S50 - S51
  • [10] Prediction of the effectiveness of tolcapone, a catechol-o-methyltransferase inhibitor, in patients with Parkinson's disease by COMT genotype.
    Chong, DJ
    Suchowersky, O
    Szumlanski, C
    Weinshilboum, RW
    Campbell, NR
    ANNALS OF NEUROLOGY, 1999, 46 (03) : 477 - 477
12